Austrian Breast & Colorectal Cancer Study Group

Science from the heart of Europe

E-LEARNING: Antibody-Drug-Conjugates: State-of-the-Art Cancer Treatments

The ABCSG E-Learning on ADCs in Breast Cancer Treatment is a joint project of ABCSG and Daiichi Sankyo.

SAVE THE DATE:
CDK4/6 inhibition in early breast cancer – Recent data and controversies?

• Study monarchE
• Study NATALEE

Paradigm shift: a changing CDK4/6 inhibitor treatment landscape – NOW ONLINE!

Cyclin-dependent kinase (CDK) 4/6 inhibitors have proven to be game changer as targeted cancer therapy of patients with hormone receptor-positive breast cancer and they have established as standard of care for the treatment of advanced HR+ breast cancer. Also, mechanisms of resistance to CDK4/6 inhibitors, biomarker analyses to better select patients who derive the greatest benefit from CDK4/6 inhibitors, in both early and advanced settings, and more issues have been elucidated.

The Changing Treatment Landscape of CDK4/6 Inhibitors
Moving From Late to Early Stages – 09 May 2022

Cyclin-dependent kinase (CDK) 4/6 inhibitors have emerged as an appealing targeted cancer therapy of patients with hormone receptor-positive breast cancer. Prior to the availability of CDK4/6 inhibitors, standard first-line therapy for patients with HR+/HER2- mBC was single-agent endocrine therapy.

New E-Learning on “ADCs in Breast Cancer Treatment”

This new e-learning on „ADCs in BC Treatment” is a joint project with Daiichi Sankyo and AstraZeneca